In 2025, the Singapore industry reported a valuation of USD 1.80 billion, in terms of market size.
As per our research consensus, the Singapore Infusion Services Market is projected to reach USD 3.01 billion by 2033, with an estimated CAGR of 6.6% during the forecast horizon.
Highly integrated hospital networks enable efficient infusion scheduling and strong biologic access discipline, limiting volatility in facility-based volumes.
Singapore Cancer Registry data confirm sustained treated cancer prevalence, supporting stable systemic therapy administration across public institutions.
DataCube Research Report (Feb 2026): This analysis uses 2024 as the actual year, 2025 as the estimated year, and calculates CAGR for the 2025-2033 period.
*Research Methodology: This report is based on DataCube’s proprietary 3-stage forecasting model, combining primary research, secondary data triangulation, and expert validation.
[Learn more]